The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Four Human Ras Homologs Differ in Their Abilities to Activate Raf-1, Induce Transformation, and Stimulate Cell Motility
Open accessAbstract
Human cells contain four homologous Ras proteins, but it is unknown whether each of these Ras proteins participates in distinct signal transduction cascades or has different biological functions. To directly address these issues, we assessed the relative ability of constitutively active (G12V) versions of each of the four Ras homologs to activate the effector protein Raf-1 in vivo. In addition, we compared their relative abilities to induce transformed foci, enable anchorage-independent growth, and stimulate cell migration. We found a distinct hierarchy between the four Ras homologs in each of the parameters studied. The hierarchies were as follows: for Raf-1 activation, Ki-Ras 4B > Ki-Ras 4A >>> N-Ras > Ha-Ras; for focus formation, Ha-Ras >/= Ki-Ras 4A >>> N-Ras = Ki-Ras 4B; for anchorage-independent growth, Ki-Ras 4A >/= N-Ras >>> Ki-Ras 4B = Ha-Ras = no growth; and for cell migration, Ki-Ras 4B >>> Ha-Ras > N-Ras = Ki-Ras 4A = no migration. Our results indicate that the four Ras homologs significantly differ in their abilities to activate Raf-1 and induce distinctly different biological responses. These studies, in conjunction with our previous report that demonstrated that the Ras homologs can be differentially activated by upstream guanine nucleotide exchange factors (Jones, M. K., and Jackson, J. H. (1998) J. Biol. Chem. 273, 1782-1787), indicate that each of the four Ras proteins may qualitatively or quantitatively participate in distinct signaling cascades and have significantly different biological roles in vivo. Importantly, these studies also suggest for the first time that the distinct and likely cooperative biological functions of the Ki-ras-encoded Ki-Ras 4A and Ki-Ras 4B proteins may help explain why constitutively activating mutations of Ki-ras, but not N-ras or Ha-ras, are frequently detected in human carcinomas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rho GTPases and the Actin Cytoskeleton
Hall, A. (1998) · Science · doi:10.1126/science.279.5350.509 · Cited by 6,140
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Cell Migration: A Physically Integrated Molecular Process
Lauffenburger, D. A., & Horwitz, A. F. (1996) · Cell · doi:10.1016/s0092-8674(00)81280-5 · Cited by 3,915
Marshall, C. J. (1995) · Cell · doi:10.1016/0092-8674(95)90401-8 · Cited by 3,906
Barbacid, M. (1987) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.56.070187.004023 · Cited by 3,885
Regulation of Cell Motility by Mitogen-activated Protein Kinase
Klemke, R. L., Cai, S., Giannini, A. L., Gallagher, P. J., Lanerolle, P. D., & Cheresh, D. A. (1997) · The Journal of Cell Biology · doi:10.1083/jcb.137.2.481 · Cited by 1,235
Self-citationFUNCTION AND REGULATION OF RAS
Lowy, D. R., & Willumsen, B. M. (1993) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.62.070193.004223 · Cited by 1,186
Increasing complexity of Ras signaling
Campbell, S. L., Khosravi-Far, R., Rossman, K. L., Clark, G. J., & Der, C. J. (1998) · Oncogene · doi:10.1038/sj.onc.1202174 · Cited by 1,079
Construction and applications of a highly transmissible murine retrovirus shuttle vector
Cepko, C. L., Roberts, B. E., & Mulligan, R. C. (1984) · Cell · doi:10.1016/0092-8674(84)90440-9 · Cited by 992
Rap1 mediates sustained MAP kinase activation induced by nerve growth factor
York, R. D., Yao, H., Dillon, T., Ellig, C. L., Eckert, S. P., McCleskey, E. W., & Stork, P. J. S. (1998) · Nature · doi:10.1038/33451 · Cited by 859
Cited by
A Comprehensive Survey of Ras Mutations in Cancer
Prior, I. A., Lewis, P. D., & Mattos, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2612 · Cited by 2,063
Ras proteins: different signals from different locations
Hancock, J. F. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1105 · Cited by 756
The Raf/MEK/ERK pathway: new concepts of activation
Peyssonnaux, C., & Eychène, A. (2001) · Biology of the Cell · doi:10.1016/s0248-4900(01)01125-x · Cited by 735
Chang, F., Steelman, L. S., Lee, J. T., Shelton, J. G., Navolanic, P. M., Blalock, W. L., Franklin, R. A., & McCubrey, J. A. (2003) · Leukemia · doi:10.1038/sj.leu.2402945 · Cited by 725
Haigis, K. M., Kendall, K. R., Wang, Y., Cheung, A., Haigis, M. C., Glickman, J. N., Niwa-Kawakita, M., Sweet-Cordero, A., Sebolt-Leopold, J., Shannon, K. M., et al. (2008) · Nature Genetics · doi:10.1038/ng.115 · Cited by 610
Ras signalling on the endoplasmic reticulum and the Golgi
Chiu, V. K., Bivona, T., Hach, A., Sajous, J. B., Silletti, J., Wiener, H., Johnson, R. L., Cox, A. D., & Philips, M. R. (2002) · Nature Cell Biology · doi:10.1038/ncb783 · Cited by 594
Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes
Sveen, A., Kilpinen, S., Ruusulehto, A., Lothe, R. A., & Skotheim, R. I. (2016) · Oncogene · doi:10.1038/onc.2015.318 · Cited by 470
Ras oncogenes and their downstream targets
Rajalingam, K., Schreck, R., Rapp, U. R., & Albert, Š. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2007.01.012 · Cited by 458
Raf proteins and cancer: B-Raf is identified as a mutational target
Mercer, K. E., & Pritchard, C. A. (2003) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(03)00016-7 · Cited by 457
Plasma membrane nanoswitches generate high-fidelity Ras signal transduction
Tian, T., Harding, A., Inder, K., Plowman, S., Parton, R. G., & Hancock, J. F. (2007) · Nature Cell Biology · doi:10.1038/ncb1615 · Cited by 407
A model for RAS mutation patterns in cancers: finding the sweet spot
Li, S., Balmain, A., & Counter, C. M. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0076-6 · Cited by 384
Identification of a Novel Ras-Regulated Proapoptotic Pathway
Khokhlatchev, A., Rabizadeh, S., Xavier, R., Nedwidek, M., Chen, T., Zhang, X.-F., Seed, B., & Avruch, J. (2002) · Current Biology · doi:10.1016/s0960-9822(02)00683-8 · Cited by 357
Embryonic lethality and fetal liver apoptosis in mice lacking the c-raf-1 gene
Mikula, M. (2001) · The EMBO Journal · doi:10.1093/emboj/20.8.1952 · Cited by 311
Blasco, R. B., Francoz, S., Santamaría, D., Cañamero, M., Dubus, P., Charron, J., Baccarini, M., & Barbacid, M. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.002 · Cited by 302
“Because K-Ras is the Ras isoform that binds and activates c-Raf more efficiently (Voice et al., 1999), it is possible that c-Raf might be essential to mediate K-Ras signaling to the Mek and Erk kinases, at least in an oncogenic setting.”
Raf: A Strategic Target for Therapeutic Development Against Cancer
Beeram, M., Patnaik, A., & Rowinsky, E. K. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.036 · Cited by 298
Oncogenic Ras in tumour progression and metastasis
Giehl, K. (2005) · Biological Chemistry · doi:10.1515/bc.2005.025 · Cited by 287
Integration of biochemical signalling in spines
Kennedy, M. B., Beale, H. C., Carlisle, H. J., & Washburn, L. R. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1685 · Cited by 286
Sebti, S. M., & Hamilton, A. D. (2000) · Oncogene · doi:10.1038/sj.onc.1204146 · Cited by 279
Regulation of substrate adhesion dynamics during cell motility
Kaverina, I., Krylyshkina, O., & Small, J. V. (2002) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(01)00171-6 · Cited by 273
Functional Specificity of Ras Isoforms: So Similar but So Different
Castellano, E., & Santos, E. (2011) · Genes & Cancer · doi:10.1177/1947601911408081 · Cited by 273
Isotype-Specific Functions of Raf Kinases
Hagemann, C., & Rapp, U. R. (1999) · Experimental Cell Research · doi:10.1006/excr.1999.4689 · Cited by 261
The complexity of targeting EGFR signalling in cancer: From expression to turnover
Sebastian, S., Settleman, J., Reshkin, S. J., Azzariti, A., Bellizzi, A., & Paradiso, A. (2006) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2006.06.001 · Cited by 260
A Comparative Analysis of Individual RAS Mutations in Cancer Biology
Muñoz-Maldonado, C., Zimmer, Y., & Medová, M. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01088 · Cited by 254
KRAS4A directly regulates hexokinase 1
Amendola, C. R., Mahaffey, J. P., Parker, S. J., Ahearn, I. M., Chen, W.-C., Zhou, M., Court, H., Shi, J., Mendoza, S. L., Morten, M. J., et al. (2019) · Nature · doi:10.1038/s41586-019-1832-9 · Cited by 203
Williams, C. L. (2003) · Cellular Signalling · doi:10.1016/s0898-6568(03)00098-6 · Cited by 188
Pharmacological targeting of RAS: recent success with direct inhibitors
O’Bryan, J. P. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2018.10.021 · Cited by 153
“For example, KRAS activates RAF proteins (BRAF and CRAF) better than HRAS whereas HRAS preferentially activates the PI3K pathway [17, 18].”
BackgroundThe role of wild type RAS isoforms in cancer
Zhou, B., Der, C. J., & Cox, A. D. (2016) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2016.07.012 · Cited by 130
Mo, S. P., Coulson, J. M., & Prior, I. A. (2018) · Biochemical Society Transactions · doi:10.1042/bst20180173 · Cited by 85
K-Ras prenylation as a potential anticancer target
Baranyi, M., Buday, L., & Hegedűs, B. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09902-w · Cited by 62
The role of wild-type RAS in oncogenic RAS transformation
Sheffels, E., & Kortum, R. L. (2021) · Genes · doi:10.3390/genes12050662 · Cited by 42
“Specifically, HRAS, NRAS, and KRAS show inverse abilities to activate PI3K/AKT signaling and RAF/MEK/ERK signaling: mutant HRAS is a potent activator of PI3K but a relatively poor activator of RAF; conversely, KRAS potently activates RAF but poorly activates PI3K [78,83,84], and NRAS shows intermediate activation of b…”
Background
Metadata
- Authors
- Voice, J. K., Klemke, R. L., Le, A., & Jackson, J. H.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 1999-06
- Volume
- 274
- Issue
- 24
- Pages
- 17164-17170
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W1989510858
- Cited by
- 288
- References
- 41
- FWCI
- 5.33
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.